-
Alexion Pharmaceuticals Is Still A Buy, Despite Rx Kanuma's Review-Date Delay
Friday, September 4, 2015 - 3:27pm | 383Read More...In a report issued Friday, Brean Capital analyst Jonathan Aschoff looks into Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) and, after some minor model adjustments, reiterated a Buy rating and $221.00 target price on the stock. The slight tweak in the firm’s financial model was triggered by...
-
Here's What Canaccord Learned After Spending A Day With Synageva's Management
Thursday, May 7, 2015 - 3:30pm | 280Read More...In a report published Thursday, Canaccord Genuity analyst Adam Walsh, MD detailed a recent meeting with Synageva Biopharma Corp (NASDAQ: GEVA)'s management team and came away "more positive" on the LAL-D commercial opportunity. Separately, Synageva has announced that Alexion Pharmaceuticals, Inc. (...
-
How Wedbush Sees The Alexion–Synageva Deal
Thursday, May 7, 2015 - 9:42am | 300Read More...In a report published Wednesday, Wedbush analyst David Nierengarten, Ph.D. commented on the merger agreement whereby Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) will acquire Synageva Biorpharma Corp (NASDAQ: GEVA) for $115 per share in cash and 0.6581 Alexion shares – valuing shares of Synageva at...
